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Abstract
Background: Coma complicates Plasmodium falciparum infection but is uncommonly associated with P. vivax. Most series of
vivax coma have been retrospective and have not utilized molecular methods to exclude mixed infections with P.
falciparum.
Methods: We prospectively enrolled patients hospitalized in Timika, Indonesia, with a Glasgow Coma Score (GCS) #10 and
P. vivax monoinfection on initial microscopy over a four year period. Hematological, biochemical, serological, radiological
and cerebrospinal fluid (CSF) examinations were performed to identify other causes of coma. Repeat microscopy, antigen
detection and polymerase chain reaction (PCR) were performed to exclude infections with other Plasmodium species.
Results: Of 24 patients fulfilling enrolment criteria, 5 had clear evidence for other non-malarial etiologies. PCR demonstrated
10 mixed infections and 3 P. falciparum monoinfections. 6 (25%) patients had vivax monoinfection and no apparent
alternative cause, with a median GCS of 9 (range 8–10) and a median coma duration of 42 (range 36–48) hours. CSF
leukocyte counts were ,10/ul (n = 3); 2 of the 3 patients without CSF examination recovered with antimalarial therapy
alone. One patient had a tremor on discharge consistent with a post-malarial neurological syndrome. No patient had other
organ dysfunction. The only death was associated with pure P. falciparum infection by PCR. Vivax monoinfection-associated
risk of coma was estimated at 1 in 29,486 clinical vivax infections with no deaths. In comparison, the risk of falciparum-
associated coma was estimated at 1 in 1,276 clinical infections with an 18.5% mortality rate.
Conclusions: P. vivax-associated coma is rare, occurring 23 times less frequently than that seen with falciparum malaria, and
is associated with a high proportion of non-malarial causes and mixed infections using PCR. The pathogenesis of coma
associated with vivax malaria, particularly the role of comorbidities, is uncertain and requires further investigation.
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Introduction
Severe complications in malaria are normally associated with
Plasmodium falciparum infections. Cerebral malaria, a serious
manifestation of falciparum malaria is associated with a 10–40%
mortality [1]. It is defined clinically as unarousable coma in the
presence of any degree of P. falciparum parasitemia without
evidence of other infectious or metabolic etiologies [2]. The
central process in the pathogenesis of coma in falciparum
malaria is thought to be microvascular obstruction resulting
from cytoadherence of parasitized red cells to activated and
dysfunctional endothelial cells [3,4]. In contrast to P. falciparum,
P. vivax has a low parasite biomass and until recently [5], was
considered unable to cytoadhere or sequester [6]. While it has
long been considered to be clinically uncomplicated, three
recent large prospective epidemiological studies from Indone-
sia, Papua New Guinea and India have challenged this
perception, associating P. vivax infections with severe manifes-
tations of disease including anemia, respiratory distress, coma
and death [7–9]. However, detailed clinical characterizations
of specific complications, particularly coma, have not been
described.
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In addition to the epidemiological studies from Indonesia and
PNG [7,8,10], 70 cases of P. vivax associated coma have been
reported since 1921 [9,11–28], the largest series being that of 12
patients from Russia published in 1943 [12]. In several reports, the
clinical information provided was not detailed enough to exclude
alternative diagnoses and the clinical presentations would not have
been classified as cerebral malaria by WHO criteria [14,19,20].
Mixed infections with P. falciparum and P. vivax are not uncommon
in severe malaria and can be notoriously difficult to diagnose [29].
Despite this the majority of the descriptions of vivax coma have
relied solely on microscopy to establish the parasitological
diagnosis, with modern methods to exclude mixed infections, eg
polymerase chain reaction (PCR) or P. falciparum antigen detection,
being applied to only 24 cases in 9 publications [9,20,21,23–28].
To clinically characterize coma in P. vivax infections, we
conducted a prospective observational study in Papua, Indonesia,
of patients admitted with impaired consciousness and P. vivax
monoinfection on the peripheral blood film, to confirm the
diagnosis and investigate associated co-morbidities.
Methods
Study Site and Patient Population
The study was conducted at the Mitra Masyarakat Hospital,
Timika, Papua, Indonesia, the only hospital in a lowland area with
unstable transmission and a high prevalence of multi-drug resistant
P. falciparum and P. vivax [30,31]. The emergency department and
wards were reviewed thrice daily. All patients with a Glasgow
coma score of #10 at the time of examination by the research
team, and a peripheral blood film reported as only P. vivax by the
hospital laboratory were prospectively enrolled. On recruitment,
history and physical examination findings were obtained using a
standardized data form and patients followed daily until discharge.
Oxygen saturation was measured with a pulse oximeter. All
patients had venous blood samples collected for investigations
including full blood counts (measured using a Coulter counter) and
routine biochemistry. Acid-base parameters and lactate were
analyzed using an iSTAT portable analyser (iSTAT Corp).
Lumbar puncture was undertaken for clinical indications at the
discretion of the treating physician, and if informed consent was
obtained from patient’s relatives. Plasma was also tested for
antibodies to Murray Valley Encephalitis, Dengue, Kunjin and
Japanese B Encephalitis viruses, using hemagglutination inhibition
and indirect fluorescent antibody testing. All patients were treated
with the recommended antimalarial treatment for severe malaria
at RSMM Hospital, intravenous quinine until October 2005 and
intravenous artesunate thereafter. Antibiotics were prescribed at
the discretion of the treating physician who was independent of the
study team.
Microscopy, Polymerase Chain Reaction, Antigen
Detection
All Giemsa-stained hospital slides at the time of enrolment were
re-examined by a research microscopist with 15 years experience
in malaria microscopy. These were considered negative for P.
falciparum if none were seen on 100 high power fields. P. falciparum
histidine rich protein 2 (HRP2) antigen was measured using the
Paracheck (Orchid Biomedical Industries, Goa, India) rapid
diagnostic test and Plasmodium species confirmed using a multiplex
polymerase chain reaction [32].
Cerebrospinal Fluid Examination
Where possible, cerebrospinal fluid (CSF) was collected,
centrifuged and processed on the day of admission. CSF was
Gram stained for bacteria and CSF white cells were quantitated
manually using a Neubauer hemocytometer. Protein and glucose
concentrations were measured by an autoanalyzer (Hitachi).
Statistical Methods
Statistical analysis was performed with STATA software
(version 9.2). Results are presented as either mean or median
(range) for continuous variables, and proportions for variables with
binary outcomes.
Ethical Approval
Written informed consent was obtained from all patients’
relatives, and ethical approval was obtained from the Health
Research Ethics Committees of the National Institute of Health
Research and Development, Indonesia and Menzies School of
Health Research, Australia.
Results
Patients
From February 2005 through November 2008, 40,160 patients
were admitted to the hospital of which 29% (11,469) had a diagnosis
of malaria (Figure 1). Plasmodium falciparum infection was present in
7647 (67%) of these admissions, P. vivax in 2443 (21%), P. malariae
153 (2%), P. ovale 3, with 1223 (11%) mixed infections by routine
hospital microscopy. Routine hospital surveillance identified a total
of 246 patients admitted with coma and microscopy confirmed
parasitemia; of these patients 174 (71%) had monoinfection with P.
falciparum, 41 (17%) monoinfection with P. vivax and 31 (13%) with
mixed infections. Of the 41 patients with P. vivax monoinfection by
routine microscopy, 24 patients were admitted with coma (GCS
#10) and were enrolled in the study.
Five patients were found to have alternative causes of coma
based on clinical, radiological and cerebrospinal fluid findings: one
with meningitis, two with head trauma and two children with
Author Summary
An estimated 132 to 391 million cases of Plasmodium vivax
occur annually, accounting for up to 50% of malaria cases
in South and East Asia. Vivax malaria is called ‘‘benign
tertian malaria’’ and is not considered to be associated
with life threatening or severe complications. Recently,
observational studies and case series or reports have
reported features of severe disease normally only seen in
falciparum malaria, including coma. However, the majority
of these reports did not exclude mixed infections using
molecular methods or estimate the risk to the population
in an endemic area. In Indonesia Papua, which has a high
rate of vivax malaria and drug resistance, we prospectively
enrolled all patients with coma and vivax monoinfection
by microscopy over a 4 year period. We excluded
falciparum malaria by molecular and antigenic methods,
and sought evidence for other central nervous system
(CNS) infections by cerebrospinal fluid microscopic exam-
ination. The majority of patients had evidence of mixed
infections with P. falciparum or non-malarial causes of
coma, however six patients had clinically significant coma,
with no evidence of falciparum malaria or other CNS
infections. The study was limited by the absence of
bacterial cultures. Our study highlights that P. vivax can be
associated with coma, but that this phenomenon is 23
times less frequent than that seen with falciparum malaria
and was not associated with a fatal outcome.
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Figure 1. Number of cases of malaria admitted to RSMM each month from February 2005 to October 2008. Black areas on bars are P.
falciparum, grey areas are P. vivax and white areas mixed infections. Black triangles are cases of vivax only on PCR. White triangles are cases of mixed
or P. falciparum on repeat microscopy, PCR or antigen testing.
doi:10.1371/journal.pntd.0001032.g001
Table 1. Baseline characteristics of patients.
Coma with only
P. vivax by PCR
Coma with only P. vivax on
microscopy but PCR positive for
mixed species or P. falciparum
Coma with P. vivax plus P. falciparum
coinfection by microscopic cross-
examination and/or HRP2 antigen
positivity, or other diagnosis
Number 6 8 10
Age (yrs) Median and range 19 [10-25] 16 [6–30] 16 [1–30]
No of Males (% total) 4 (66%) 6 (75%) 8 (80%)
No of Indigenous Papuans (% total) 4 (83%) 6 (75%) 9 (90%)
Glasgow Coma Score Median [Range] 9 [8–10] 8 [5–11] 10 [4–11]
Time to recovery from coma (hrs) Median [Range] 42 [24–48] 48 [18–60] 84 [16–192]
Neurological sequelae Yes No No
Fatal outcome (n) 0 1 0
Hemoglobin (g/dl) Median(Range) 11 (9.4–11.7) 10.1 (7.9–12.6) 10.8 (3.9–14.4)
Leukocytes (/ml) Median (Range) 9600 (8500–11400) 9250 (6800–13800) 10100 (4900–39600)
Platelets (x 103/ml) Median (Range) 178 (133–221) 154 (74–377) 94 (32–328)
Glucose (mmol/L) Median (Range) 6.1 (4.8–7.8) 5.8 (4.675–8.3) 7.5 (4.8–217)
Lumbar Puncture Obtained 3/6 (50%) 6/8 (75%) 7/10 (70%)
CSF cells.50/ml 0/3 (0%) 0/6 (0%) 1/7 (14%)
doi:10.1371/journal.pntd.0001032.t001
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severe pneumonia. On re-examination of the blood film and by
antigen detection, five (20%) patients were found to be infected
with both P. falciparum and P. vivax, with a median parasitaemia of
258/mL and 1273/mL respectively. These 5 mixed infections were
confirmed by PCR analysis. PCR identified an additional 5
patients with mixed infections and 3 with P. falciparum monoinfec-
tion. In total, six (25%) patients had no evidence of mixed
infections by microscopy, antigen and PCR testing and no clinical
or laboratory evidence of an alternative diagnosis to account for
the coma. The baseline characteristics, hematological and
biochemical indices of all 24 patients are summarized in
Table 1. Two of the six cases with PCR-confirmed P. vivax
monoinfection were recruited during a two week period in
October 2005 (Figure 1).
Characteristics of the 6 individuals with confirmed pure P. vivax
infection are detailed in Table 2. All were adolescents or young
adults (aged 10–25) with a history of fever (median duration of
fever prior to admission of 1 day (range: 1–7)), and a short history
of decreased conscious level prior to presentation (1 hour [range:
0.5–2]). None of the patients had seizure activity reported prior to
or during the hospital admission. None were reported to have had
a previous history or a family history of neurological disease, or to
have ingested medication (including antimalarials) or traditional
medicines in the two months prior to presentation.
On examination all six patients were normotensive, with normal
respiratory rate and oxygen saturation. The median Glasgow
coma score (GCS) was 9 (range: 8–10). There were no focal or
lateralizing neurological signs. Hepatosplenomegaly was present in
two patients. There were no petechiae or purpuric lesions. Chest
auscultation was normal. Chest x-rays were performed in 3
patients, none of which showed infiltrates.
Biochemistry and Cerebrospinal Fluid
Peripheral blood parasite counts were low with a median of
212/ml (Range: 57 to 2131/mL) (Table 3). All patients were
anemic, one had a slightly elevated leukocyte count (11,400/ml)
but none had significant thrombocytopenia (Table 3). Renal
function was normal with no significant abnormalities in
electrolytes or blood glucose concentration. No patient had
significant acidosis (venous bicarbonate ,15 meq/L), although
two had elevated venous blood lactate levels (3.1 mmol/L and
5.1 mmol/L).
Cerebrospinal fluid (CSF) was obtained from three patients; cell
counts were all less than 10/ml, with a normal protein
concentration and a CSF to blood glucose ratio .0.4 (Table 2).
Acute plasma serology for flaviviruses did not show evidence of
recent arbovirus infection in any patient.
Treatment and Outcome
All six patients received intravenous artesunate, with four
receiving additional antibiotics. The two patients without CSF
examination recovered without antibiotic therapy. The median
time for parasite clearance was 1.5 days (range: 1–2 days) with
patients taking a median of 42 hrs (range: 36–48 hrs) to recover to
a normal Glasgow coma score; Table 2. One patient had
neurological sequelae after recovery from coma, consisting of an
action and postural tremor with myoclonus (Video S1). Although
improved, tremor/myoclonus was still present at the time of
hospital discharge on day 5. The patient was subsequently lost to
follow up. All patients with P. vivax monoinfection survived; the
sole fatality was found in a patient with initial hospital microscopy
showing P. vivax but a PCR result showing P. falciparum
monoinfection.
Table 2. Clinical findings in the six patients with coma and PCR-confirmed monoinfection with P. vivax.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (yrs) 20 18 15 25 10 19
Sex Male Male Male Male Female Female
Ethnicity Non Papuan Papuan Papuan Papuan Papuan Papuan
No of days with fever 3 1 1 7 1 14
Coma duration (prior to admission) hours 0.5 1 2.3 2 0.5 2
Convulsions (prior to admission) None None None None None None
Systolic Blood Pressure (mmHg) 110 111 110 120 116 110
Diastolic Blood Pressure (mmHg) 70 50 70 70 60 70
Respiratory Rate (/min) 24 25 24 24 26 28
Oxygen Saturation (%) 94 99 99 100 100 97
Temperature (OC) 37.0 39.1 36.8 36.0 38.7 36.7
Liver/Spleen palpable No Yes No No No Yes
Glasgow Coma Score (on enrolment) 8 8 10 9 10 8
Time to recover to GCS 15 (hrs) 48 36 36 48 48 48
Parasite Clearance (days) 2 2 1 1 1 1
Neurological Deficit No No Yes No No No
Anti-malarial Therapy Artesunate Artesunate Artesunate Artesunate Artesunate Artesunate
Antibiotics No No Yes Yes Yes Yes
Lumbar Puncture Obtained No No Yes Yes Yes No
doi:10.1371/journal.pntd.0001032.t002
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Population Risk
Over the 46 months of the study an estimated total of 176,915
clinical episodes of P. vivax were recorded in the community [31],
and 2443 admitted to hospital. Assuming that 6 of the patients
admitted with decreased conscious level were actually attributable
to P. vivax, then the overall risk of vivax-attributable coma is
estimated to be 1 in 29,486 clinical vivax infections in the
community (incidence 3.4 per 100,000 [95%CI: 1.24–7.38]) and 1
in 407 vivax admissions to hospital (incidence 246 per 100,000
[95%CI: 90.2–533.8]). Comparably active surveillance of coma
(GCS #10) associated with Plasmodium falciparum recorded 70 cases
for the 16 month period from February 2005 to May 2006, with
an estimated 89,375 cases of falciparum malaria in the community
and 3,105 who were inpatients during the same time period. In
comparison to vivax malaria, the risk of falciparum-associated
coma was 1 in 1,276 cases in the community (incidence 78.3 per
100,000 [95%CI: 61.1–98.9]) and 1 in 44 hospital admissions
(incidence 2,254 per 100,000 [95%CI: 1762–2840]). Estimates for
both species are conservative, assuming that all patients with coma
will have presented to the hospital. Mortality in falciparum-
associated coma was 18.5% (13/70) compared to 0% (0/6) in
vivax-associated coma (p= 0.2).
Discussion
We report a prospective case series of 24 patients with cerebral
malaria defined by World Health Organization criteria associated
with P. vivax infection on admission microscopy. A high proportion
of these had non-malarial causes of coma (21%), mixed-species
infections (42%) or P. falciparum infection (12%). P. vivax was the
only identified potential cause in 25% of these patients.
Cerebrospinal fluid (CSF) findings in these patients were not
consistent with other central nervous system infections, such as
encephalitis. While microbiological laboratory resources were
limited and culture facilities absent, the clinical, hematological and
clinical biochemistry results did not suggest bacterial sepsis, or
metabolic or toxic etiologies for the unarousable reversible coma.
The absence of seizures prior to or during admission makes
prolonged post-ictal coma unlikely.
Early reports of vivax associated coma included temperate
countries such as Russia, Italy and the USA [12–14]; however
since 1970, all other case reports and clinical series have come
from India and Pakistan [9,16–21,23–28] with a single case report
from Turkey [22]. With the exception of a recent prospective
study from India [9], these have been retrospective case reports or
series. Of the 70 cases reported, only 9 studies comprising 24
patients tested for mixed infections using either antigen detection
or molecular methods. It is significant that one third of the patients
in our study were diagnosed as having mixed or P. falciparum
infections after PCR testing which had not been previously
identified by microscopy cross-checking and antigen testing.
One patient developed a new postural and intention tremor
with myoclonic jerks after recovery from coma, a presentation
similar to post-malarial neurological complications reported after
recovery from cerebral malaria due to P. falciparum [33]. Other
neurological complications previously associated with P. vivax
such as inflammatory demyelinating polyneuropathy and facial
paralysis were not seen in our study [9]. The history of fever, lack
of focal neurological signs, non-inflammatory cerebrospinal fluid
and the time to recovery from coma are similar to the features of
the coma seen in falciparum malaria [1,2]. Unlike falciparum
malaria [1,2] and reports of vivax coma from India [9] we did not
find other organ dysfunction such as acute renal failure, acute
lung injury or hyperbilirubinemia. Acidosis and increased lactic
acid concentrations related to the impaired microcirculatory flow
are markers of severity in falciparum malaria [1]. In this study, no
patient had significant acidosis as defined by WHO criteria for
severe malaria, but two (33%) had elevated lactic acid levels, one
markedly so. There were also no fatalities, in contrast to the
mortality rates of 18.5% seen in falciparum-associated coma in
Timika and the 15%-40% in cerebral malaria from P. falciparum
reported elsewhere [1], although the small numbers do not allow
Table 3. Laboratory findings in the six patients with coma and PCR-confirmed monoinfection with P. vivax.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Hemoglobin (g/L) 122 109 129 126 111 103
Leukocytes (/ml) 8500 9400 11400 10100 8700 9800
Platelets (x 103/ml) 133 221 145 182 183 173
Sodium (mmol/L) 138 140 134 142 140 136
Potassium (mmol/L) 3.1 3.6 3.8 3.0 3.3 3.5
Chloride (mmol/L) 104 106 103 106 104 103
Glucose (mmol/L) 7.7 6.16 7.81 5.5 5.39 4.9
Creatinine 0.74 1.2 0.67 0.8 0.8 0.61
pH 7.43 7.37 7.44 7.45 7.40 ND
Bicarbonate (mmol/L) 27.5 17.6 23.8 20.6 23.5 ND
Base Excess 3 28 0 3 21 ND
Lactate (mmol/L) 1.28 5.13 1.9 3.1 ND ND
CSF Cell Count (/ml) ND ND 7 3 7 ND
CSF Glucose (mg/dl) ND ND 64 90 53 ND
CSF Protein (mg/dl) ND ND 1 5 7 ND
Parasitemia (/ml) 213 94 57 656 2131 196
PCR P. vivax P. vivax P. vivax P. vivax P.vivax P. vivax
All values are for venous blood except where indicated.
doi:10.1371/journal.pntd.0001032.t003
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a confident estimate of case-fatality rates in vivax-associated
coma.
The results suggest that P. vivax infection may be a plausible,
albeit rare cause of coma as well as the post-treatment
neurological syndrome, although lack of microbiological facilities
did not allow us to comprehensively exclude other infectious
causes. In Africa, autopsy studies show that up to 23% of cases of
cerebral malaria diagnosed by careful clinical definitions and P.
falciparum peripheral parasitemia may be due to other etiologies
[34]. The temporal clustering of several cases in October 2005
could be due to unidentified infectious etiologies being respon-
sible for the fever and coma, with incidental P. vivax parasitemia.
Limitations of our study include our inability to exclude viral
encephalitis, although conclusive demonstration of a causative
pathogen is also difficult in better resourced settings due to the
limitations of current diagnostic technologies. However in those
undergoing lumbar puncture, CSF findings did not suggest viral
encephalitis. Furthermore, death or profound neurological
sequelae, characteristic of endemic arboviral encephalitides in
this region (eg Japanese B and Murray Valley Encephalitis
viruses), were not seen. Other viral comas such as herpes simplex
encephalitis are unlikely given the relatively short time to full
recovery without specific anti-viral therapy. Lack of bacterial
culture facilities did not allow us to exclude concurrent bacterial
infections. Nevertheless, two of the five vivax coma patients
recovered without antibiotic therapy and CSF findings did not
suggest meningitis. We did not test for toxins which could cause
coma, but all patients denied use of traditional or other
medications prior to admission.
The pathogenesis of coma in falciparum malaria is not fully
understood, and comorbidities are increasingly recognized as
contributing factors even where coma is clearly attributable to P.
falciparum infection [35]. Much less is known about potential
mechanisms underlying coma in P. vivax [6]. In P. falciparum
infection, cytoadherence of parasitized erythrocytes to endothelial
adhesion receptors [3], and endothelial activation and dysfunction
resulting from decreased nitric oxide bioavailability [4] contribute
to increased parasite sequestration and impaired microcirculatory
flow. P. vivax infected erythrocytes have been recently shown to
cytoadhere to endothelial cells via chondroitin sulfate A and
intercellular adhesion molecule 1 (ICAM-1), both expressed on
brain endothelial cells, although at a frequency 10-fold less than P.
falciparum [5]. This could account for the lower incidence of coma
in vivax malaria although the degree of endothelial activation is
greater in vivax than falciparum malaria [36]. Increased von
Willebrand Factor (vWF) and decreased levels of the vWF cleaving
protease, ADAMTS 13, have recently been described in
uncomplicated vivax malaria and severe falciparum malaria
[37,38], and could contribute to microvascular obstruction.
However, their role in the pathogenesis of severe vivax remains
undefined. The lack of renal failure and significant thrombocyto-
penia or hemolytic anemia in vivax-associated coma does not
suggest a thrombotic thrombocytopenic purpura-like syndrome
due to altered vWF/ADAMTS13. Peripheral parasitemias in our
series were all low, but whether this reflects a low biomass or is due
to parasite sequestration or pooling elsewhere could not be
determined.
A significant proportion of patients in our study were only
diagnosed as having mixed infections by PCR, with negative
results for P. falciparum on repeated microscopy and antigen
detection testing. In these patients, the small P. falciparum
parasite biomass should not result in clinical coma based on
prevailing sequestration-based concepts of coma, and therefore
one cannot exclude a contribution from P. vivax to coma in these
patients.
Lung function studies suggest that pulmonary complications in
vivax malaria may be related to pulmonary vascular accumulation
of inflammatory cells with or without sequestration of P. vivax-
parasitized erythrocytes [39]. A similar process might occur in
cerebral malaria associated with P. vivax but has not been
described. Sepsis-associated encephalopathy, observed in critically
ill septic patients, has been associated with increased tumor
necrosis factor (TNF-alpha) (32). Concentrations of TNF-a [40]
and other pro-inflammatory cytokines [36] can be higher in vivax
compared to falciparum malaria, and have been linked to vivax-
associated disease severity in a series without central nervous
system manifestations [41], however the role of inflammatory
responses in vivax-associated coma are not known [6].
In summary, we describe a prospective case series of reversible
coma associated with pure P. vivax infection with no overt clinical
evidence for other central nervous system infections. All patients
survived following treatment with intravenous artesunate; however
one patient developed a tremor and myoclonus after recovery
from coma, consistent with a post-malarial neurological syndrome
previously described with falciparum cerebral malaria. Our study
shows that compared to falciparum malaria, coma is a rare
syndrome associated with pure vivax malaria, occurring in
approximately 3.4 per 100,000 clinical episodes of infection. The
role(s) of comorbidities and the pathogenic mechanisms underlying
coma associated with P. vivax are not clear and warrant further
investigation.
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